

— FACTOR VIII ACTIVITY · CHROMOGENIC & CLOTTING · EMICIZUMAB-INSENSITIVE MEASUREMENT

Measure FVIII activity — *even when emicizumab is present.*

Emicizumab mimics activated FVIII and distorts standard FVIII assays. The bovine-FX **BIOPHEN™ FVIII Variant** is insensitive to emicizumab — it reads **endogenous or infused FVIII** in the sample; the human-reagent **FVIII:C** is the routine assay and the one that **measures emicizumab**; a **one-stage clotting** method completes the panel — all backed by matched calibration and QC.

FEATURED · EMICIZUMAB-INSENSITIVE

A227102

\$461

RUO (US) · CE-IVD (EU)

BIOPHEN™ FVIII Variant

Bovine Factor X · insensitive to emicizumab

- Chromogenic FVIII:C on **bovine Factor X** — emicizumab does not react with bovine FX, so the assay reads only the sample's FVIII.
- Complete kit — R1 bovine FX, R2 activation reagent, R3 Sxa-11 substrate, R4 buffer.
- Quantifies **endogenous or infused FVIII** separately from emicizumab — plasma or concentrates, automated.
- For **FVIII deficiency** & factor-replacement testing (except emicizumab).

STANDARD METHODS — ACTIVITY BY CHROMOGENIC OR CLOTTING

CHROMOGENIC · HUMAN REAGENTS

BIOPHEN™ FVIII:C

Routine chromogenic FVIII:C for **plasma & concentrates**, two working ranges. Human FIXa/FX — validated to **measure emicizumab FVIII-like activity**. 2×2.5 mL (A221402) · 2×6 mL (A221406).

A221402 / A221406
RUO · CE-IVD · HCL

\$549–965

CLOTTING · ONE-STAGE (APTT)

FVIII:C — Deficient Plasma

Classic **one-stage APTT-based FVIII:C**, run on **FVIII:C Deficient Plasma with VWF (<1% residual)** as substrate. **Oversensitive when emicizumab is present — use the Variant instead.**

ADP040K · 6×1 mL
RUO · CE-IVD · HCL

\$385

CALIBRATED & CONTROLLED — EVERY METHOD, MATCHED

REFERENCE CALIBRATOR & QC PLASMAS

BIOPHEN™ Plasma Calibrator

18-analyte reference plasma; assigns FVIII and calibrates both clotting & chromogenic. **A222101**

Normal Control Plasma

Normal-range QC across factor activities · 12×1 mL. **A223201**

Abnormal Control Plasma

Pathological-range QC plasma. **A223301**

The chromogenic FVIII Variant and FVIII:C kits contain their working reagents; activity is assigned against the Plasma Calibrator above.

Complete the workup —

ZYMUTEST™ Anti-FVIII IgG · inhibitor ELISA (ARK039A)

SELECTED REFERENCES BIOPHEN™ FVIII:C (human factors) used for FVIII/emicizumab pharmacodynamics in the pivotal **HAVEN 1** trial — *Res. Pract. Thromb. Haemost.* (PMC7895541). · One-stage vs bovine- vs human-chromogenic (BIOPHEN FVIII:C) in emicizumab-treated patients — *Blood* 2021;138(Suppl 1):4234. · Analytical performance & diagnostic accuracy of BIOPHEN™ FVIII:C in haemophilia A — Novembrino et al., *Int. J. Lab. Hematol.* 2019.

Regulatory: BIOPHEN™ FVIII Variant (A227102), BIOPHEN™ FVIII:C (A221402 / A221406), FVIII:C Deficient Plasma (ADP040K), the BIOPHEN™ Plasma Calibrator (A222101), Normal / Abnormal Control Plasmas (A223201 / A223301) and ZYMUTEST™ Anti-FVIII IgG (ARK039A) are **For Research Use Only** in the United States; **CE-IVD** in Europe and **Health Canada** licensed (–CAN configurations). The Variant (bovine FX) is insensitive to emicizumab; human-reagent FVIII:C detects emicizumab; one-stage clotting is oversensitive when emicizumab is present. Pricing shown is US list and subject to change. Therapeutic agents named are referenced as analytes / scientific context and are not Aniara products. © 2026 Aniara Diagnostica, Inc.